Latest Drugs, Latest Approval in Anti-angiogenic ophthalmic agents

What are Anti-angiogenic ophthalmic agents?

Anti-angiogenic ophthalmic agents act as vascular endothelial growth factor (VEGF) antagonists. When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. During the generation of new blood vessels in the retina, if the blood vessels do not generate properly it causes leaking. This can lead to loss of vision.

Anti-angiogenic ophthalmic agents are used to stop neovascularization in age related macular degeneration.

Name Updated
Lucentis (Ranibizumab (ophthalmic) [ ra-nib-i-zue-mab-off-thal-mik ]) 05-Sep-2023
Eylea pre-filled syringe (Aflibercept ophthalmic [ a-flib-er-sept-off-thal-mik ]) 29-Aug-2023
Brolucizumab ophthalmic (Brolucizumab ophthalmic [ broe-lue-siz-ue-mab ]) 15-Aug-2023
Aflibercept ophthalmic (Aflibercept ophthalmic [ a-flib-er-sept-off-thal-mik ]) 13-Aug-2023
Ranibizumab (ophthalmic) (Ranibizumab (ophthalmic) [ ra-nib-i-zue-mab-off-thal-mik ]) 12-Aug-2023
Susvimo (Ranibizumab) 05-Aug-2023
Vabysmo (Faricimab-svoa) 14-Jul-2023
Macugen (Pegaptanib ophthalmic injection [ peg-ap-ta-nib ]) 13-Jul-2023
Lucentis (Ranibizumab (ophthalmic) [ ra-nib-i-zue-mab-off-thal-mik ]) 13-Jul-2023
Cimerli (Ranibizumab-eqrn (ophthalmic)) 13-Jul-2023
Byooviz (Ranibizumab (ophthalmic)) 13-Jul-2023
Beovu (Brolucizumab-dbll) 12-Jul-2023
Eylea and eylea hd (Aflibercept ophthalmic) 10-Jul-2023